



*Ifw*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Zang et al.

FILED: July 02, 2003

SERIAL NO.: 10/612,468

FOR: T Cell Receptor CDR3 Sequence and Methods  
for Detecting and Treating Rheumatoid Arthritis

§ ART UNIT:  
§ 1644  
§  
§ EXAMINER:  
§ Juedes, A.E.  
§  
§ DOCKET:  
§ D6622

Mail Stop Non-Fee Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**RESPONSE TO RESTRICTION REQUIREMENT AND  
CERTIFICATE OF MAILING UNDER 37 CFR 1.8**


Dear Sir:

In response to a Restriction Requirement, mailed March 09, 2006, for the above-referenced application, Applicants elect Group 4, claims 10-11, 13-14 and 42-44 drawn to an isolated peptide derived from a BV16 TCR, or an isolated peptide comprising SEQ ID NO: 4, SQD, SLL or SEQ ID NO: 5 and pharmaceutical compositions thereof, without traverse. Applicant further provisionally elects the species SEQ ID NO: 4, with traverse. Claims 10-11, 13-14 and 42-44 read on the elected species.

I certify under 37 CFR 1.8 that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date below and is addressed to MS Non-Fee Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. Please return the enclosed postcard acknowledging receipt of this correspondence.

Respectfully submitted,

Date: Aug 10, 2006  
ADLER & ASSOCIATES  
8011 Candle Lane  
Houston, Texas 77071  
Tel: (713) 270-5391  
Fax: (713) 270-5361  
BADLER1@houston.rr.com

  
Benjamin Aaron Adler, Ph.D., J.D.  
Registration No. 35,423  
Counsel for Applicant